Citations

Clear

6273 citation(s) found for "To, Andrew".

Faculty Opinions recommendation of HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs.
Rizza, Stacey A. , Badley, Andrew D.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 21, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.2577978.2232078 Get It

Effectiveness of First-Line Management Strategies for Stage I Follicular Lymphoma: Analysis of the National LymphoCare Study
Friedberg, Jonathan W. , Byrtek, Michelle, Link, Brian K. , Flowers, Christopher R. , Hainsworth, John D. , Cerhan, James R. , Zelenetz, Andrew D. , Hirata, Jamie , Miller, Thomas P. , Taylor, Michael D. , Cerhan, James R , Link, Brian K , Zelenetz, Andrew D

Mayo Clinic

Journal of Clinical Oncology | August 21, 2012 | Volume: 30 | Issue: 27 | Pages: 3368-3375

10.1200/jco.2011.40.6546 | PMID 22915662 Get It

PurposeThe optimal management of stage I follicular lymphoma, according to consensus guidelines, is based on uncontrolled experiences of select institutions. Diverse treatment approaches are used despite guidelines that recommend radiation therapy (XRT).Patients and MethodsWe analyzed outcomes of patients with stage I follicular lymphoma enrolled onto the National LymphoCare database.ResultsOf 471 patients with stage I follicular lymphoma, 206 patients underwent rigorous staging as defined by both a bone marrow aspirate and biopsy and an imaging study (a computed tomography [CT] scan of the whole body, a positron emission tomography [PET]/CT scan, or both). Rigorously staged patients had superior progression-free survival (PFS) compared with nonrigorously staged patients (hazard ratio [HR], 0.63). Treatments given to rigorously staged patients were rituximab/chemotherapy (R-chemo; 28%), XRT (27%), observation (17%), systemic therapy + XRT (13%), rituximab monotherapy (12%), and other (3%). With a median follow-up of 57 months for PFS, there were 44 progression events (in 21% of patients) for rigorously staged patients. For these patients, PFS was significantly improved with either R-chemo or systemic therapy + XRT compared with patients receiving XRT alone after adjustment for histology, LDH, and the presence of B symptoms. There were no differences in overall survival.ConclusionIn this largest, prospectively enrolled group of patients with stage I follicular lymphoma, variable treatment approaches resulted in similar excellent outcomes, which challenges the paradigm that XRT should be standard for this presentation.
Faculty Opinions recommendation of Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue.
Badley, Andrew D. , Cummins, Nathan W.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 20, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.7582957.9635054 Get It

Faculty Opinions recommendation of Markers of endothelial dysfunction, coagulation and tissue fibrosis independently predict venous thromboembolism in HIV.
Badley, Andrew D. , Cummins, Nathan W.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 20, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.10037966.10786067 Get It

Faculty Opinions recommendation of Antibody and B-cell responses may control circulating lipopolysaccharide in patients with HIV infection.
Badley, Andrew D. , Cummins, Nathan W.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 20, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.11289958.12287058 Get It

Faculty Opinions recommendation of Systems biology of vaccination for seasonal influenza in humans.
Badley, Andrew D. , Cummins, Nathan W. , Badley, Andrew D

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 20, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.12673956.13938055 Get It

Faculty Opinions recommendation of Association of osteonecrosis and osteoporosis in HIV-1-infected patients.
Badley, Andrew D. , Cummins, Nathan W.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 20, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.13357070.14726418 Get It

Chronic pain as a manifestation of potassium channel-complex autoimmunity
Klein, Christopher J. , Lennon, Vanda A. , Aston, Paula A., McKeon, Andrew , Pittock, Sean J. , Pittock, S J , Klein, Christopher J , McKeon, Andrew

Mayo Clinic

Neurology | August 15, 2012 | Volume: 79 | Issue: 11 | Pages: 1136-1144

10.1212/wnl.0b013e3182698cab | PMID 22895588 Get It

Abstract LB-423: Whole genome comparisons of pre- and post- aromatase inhibitor treatment in estrogen receptor positive breast cancer
Li, Ding, Shen, Dong , Wallis, John W., Tine, Brian Andrew Van, Crowder, Robert J., Snider, Jacqueline, Koboldt, Daniel C. , Schierding, William , McMichael, Joshua F. , Kandoth, Cyriac , Wendl, Michael C. , DeSchryver, Katherine, Allred, D. Craig, Unzeitig, Gary, Margenthaler, Julie, Babiera, Gildy V., Marcom, P. Kelly, Guenther, J. Michael, Leitch, Marilyn , Tao, Yu , Fulton, Lucinda , Fulton, Robert S. , Oberkfell, Ben, Du, Feiyu, Demeter, Ryan, Vickery, Tammi L. , McDonald, Sandra , Dooling, David J., Ota, David M., Chang, Li‐Wei , Bose, Ron , Wilson, Richard K. , Ellis, Matthew J. , Luo, Jingqin , Suman, Vera J. , Hoog, Jeremy , Ballman, Karla V. , Chen, Ken , Miller, Christopher A. , Lu, Charles , Harris, Christopher , McLellan, Michael D. , Esserman, Laura J. , Hunt, Kelly K. , Olson, John A. , Harrison, Michelle , Griffith, Malachi , Watson, Mark A. , Ley, Timothy James , Mardis, Elaine R.

Mayo Clinic

Cancer Research | August 13, 2012 | Volume: 72 | Issue: 8_Supplement | Pages: LB-423-LB-423

10.1158/1538-7445.am2012-lb-423 Get It

Abstract Background: Estrogen receptors are over-expressed in around 70% of breast cancer cases. The genetic changes that occur during aromatase inhibitor (AI) treatment are not well understood and may differ depending upon the patient's response phenotype. Methods: We performed whole genome sequencing (WGS) of matched blood, pre-treatment, and post-treatment biopsy samples from 22 estrogen receptor positive breast cancer patients treated with neoadjuvant aromatase inhibitors. For 5 cases, we performed the whole genome sequencing (WGS) on patients’ matched normal, two pre AI-treatment, and two post AI-treatment DNA isolates from biopsy samples. We validated all putative coding and non-coding somatic mutations using deep sequencing. By comparing the validated somatic mutations from pre- and post- AI treatment biopsy samples, we were able to determine the alterations in the tumor genomes. In every case we defined the clonal architecture of each pair of pre-treatment and post-treatment biopsy samples by comparing the variant allele frequencies from thousands of validated somatic mutations. Results: Comparisons of the two pre AI-treatment biopsy samples from the same patient indicates that the variant allele frequencies of mutations showed high concordances in all 5 cases, 0.74 to 0.95 range of correlation coefficient. Only a small percentage of somatic mutations were detected in one pre-treatment sample and not the other (4.65% overall). In comparing the somatic variations between pre-treatment and matched post-treatment biopsy samples in 22 cases, we found that patients with good clinical response to AI treatment retained known driver mutations only in their pre-treatment tumors. Conversely, those patients with poor clinical response presented new driver mutations in their post-treatment samples. Furthermore, the variant allele frequency for most mutated genes decreased in post AI treatment samples for patients with good AI treatment response; on the contrary, the variant allele frequency increased for patients with poor clinical response. Conclusions: From WGS of matched normal, pre-treatment, and post-treatment biopsy samples, we identified new driver genes mutated in patients with poor clinical response, while patients with good clinical response had lost mutated driver genes in their post-treatment biopsy samples. The genetic landscape revealed by WGS of pre-treatment and post-treatment biopsy samples reveals mutational repertoires are remodeled by AI therapy. This finding suggests deep sequencing of AI treated samples will be necessary to reveal the complete complement of mutations present in a patient's tumor. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-423. doi:1538-7445.AM2012-LB-423
Abstract 2927: MicroRNA binding site polymorphisms influence ovarian cancer risk in the collaborative oncological gene-environment study
Permuth‐Wey, Jennifer, Zhihua, Chen, Birrer, M., Cunningham, Julie M. , Fenstermacher, David, Gayther, Simon A. , Gentry-Maharaj, Alexandra, Iversen, Edwin S., McLaughlin, John, Menon, Usha , Narod, Steven A. , Phelan, Catherine M., Song, Honglin , Sutphen, Rebecca , Terry, Kathryn L. , Wentzensen, Nicolas , Lancaster, Johnathan M., Cheng, Jin Q. , Berchuk, Andrew, Schildkraut, Joellen M. , Goode, Ellen L. , Sellers, Thomas A. , Lin, Hui‐Yi , Tsai, Ya-Yu , Zhihua, Chen, Chen, Y. Ann , Barnholtz‐Sloan, Jill S. , Chanock, Stephen Jacob , Cramer, Daniel W. , Fridley, Brooke L. , García‐Closas, Montserrat , Bosquet, Jesús González , Jim, Heather , McLaughlin, John, Monteiro, Álvaro N.A. , Ramus, Susan J. , Risch, Harvey A. , Tyrer, Jonathan P. , Vierkant, Robert A. , Pharoah, Paul D.P. , Menon, Usha

Mayo Clinic

Cancer Research | August 13, 2012 | Volume: 72 | Issue: 8_Supplement | Pages: 2927-2927

10.1158/1538-7445.am2012-2927 Get It

Abstract Mi(cro)RNAs are short non-coding RNA molecules that play a key role in carcinogenesis by regulating tumor suppressors and oncogenes. Published data has implicated miRNAs in ovarian cancer (OC) development and progression, and we hypothesize that single nucleotide polymorphisms (SNPs) in sites of miRNA: messenger RNA (mRNA) binding may influence OC risk by altering expression levels of targeted mRNAs. To evaluate associations between SNPs in miRNA binding sites and OC risk, we used bioinformatics tools and public databases to identify miRNA binding SNPs relevant to ovarian cancer. We then evaluated the frequency of approximately 1,100 SNPs in ∼20,000 epithelial OC cases and 20,000 controls represented in the international Collaborative Oncological Gene-environment Study. Unconditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) between genotypes and case status, with adjustment for the first five principal components representing European ancestry. Log-additive genetic models were applied to each SNP, modeling the number of copies of the minor allele. Subgroup analysis was conducted for serous adenocarcinomas, the most predominant histologic subtype of epithelial OC. Preliminary analysis of 11,215 invasive epithelial OCs and 15,910 controls included four SNPs with P<10−6 and 1 SNP with P<10−5. Analysis of 6,215 invasive serous adenocarcinomas revealed two SNPs with P<10−7 and three SNPs with P<10−6. Noteworthy is rs6104808, a C>T SNP predicted to reside in a highly conserved miRNA binding site of BTBD3 (BTB POZ domain containing 3), a transcription factor suggested to be involved in cell proliferation, cancer progression, and response to platinum-based chemotherapy. rs6104808 was associated with a decreased risk of OC overall (OR (95% CI): 0.42 (0.28-0.62), P=1.26 x 10−5)), and the association was stronger among cases with serous adenocarcinoma (OR (95% CI): 0.30 (0.17-0.50), P=9.89 x 10−6)). This represents the largest, most comprehensive epidemiologic study to date to evaluate associations between miRNA binding site SNPs and OC susceptibility. Although based on a preliminary analysis, these data suggest a significant role and putative biological mechanism for common germline variants in miRNA binding sites leading to cancer development. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2927. doi:1538-7445.AM2012-2927